Screener
Candel Therapeutics, Inc. CADL Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Interest expense | (1,564) | (306) |
| Change in fair value of warrant liabilities | 7,643 | 14,881 |
| Total other income, net | 7,423 | 15,509 |
| Net income (loss) and comprehensive income (loss) | $(8,861) | $7,379 |
| Net income (loss) per share, basic | $(0.14) | $0.15 |
| Weighted-average common shares outstanding, basic | 62,361,897 | 50,482,278 |
| Net income (loss) per share, diluted | $(0.14) | $0.13 |
| Weighted-average common shares outstanding, diluted | 62,361,897 | 54,765,842 |
Item 1. Financial Statements.
FAQ
- What is Candel Therapeutics, Inc.'s net income?
- Candel Therapeutics, Inc. (CADL) reported net income of -$8.86M in Q1 2026.
- How has Candel Therapeutics, Inc.'s net income changed year-over-year?
- Candel Therapeutics, Inc.'s net income decreased by 220.1% year-over-year, from $7.38M to -$8.86M.
- What is the long-term trend for Candel Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s net income has grown at a 0.3% compound annual growth rate (CAGR), from -$37.72M to -$38.18M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Candel Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude